Senior Leadership The Cancer Center requests support (16.2 calendar months, 1.35 FTE, $334,153) for an experienced and enhanced Senior Leadership team that includes Shelton Earp, MD (Director) and eight Associate Directors, including: Albert Baldwin, PhD (Basic Sciences), William Marzluff, PhD (Basic Science Cores), Richard Goldberg, MD (Clinical Research);Lisa Carey, MD (Clinical Science), Ned Sharpless MD (Translational Science);Tom Shea (Clinical Outreach), Andy Olshan (Population Sciences), and Michael O'Malley, PhD (Administration and Planning). The team has been strengthened by the addition of Drs. Carey, Sharpless, Shea, and Olshan. These new leaders join a stable group, almost all of whom have been with the Center for more than 15 years. The Director and Senior Leaders interact frequently. In addition to multiple individual interactions, the Senior Leadership team meets weekly with the Director. Senior Leaders are members of the Center's Program Planning Committee, which meets monthly. They are also active participants in their respective research programs and interact scientifically with the Program Leaders and program members. They interact with the Center's visitors, meeting individually, for example, with most of the seminar speakers to discuss the Center's development. Senior (and Program) Leaders are intimately involved in recruiting, serving as chairs or members of all the search committees. They contribute significantly to the Center's strategic planning process and the overall planning and evaluation effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594110
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$271,532
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Chao, Yvonne L; Pecot, Chad V (2018) Immunotherapy combinations emerging in non-small-cell lung cancer. Immunotherapy 10:627-629
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Spencer, Jennifer C; Brewer, Noel T; Trogdon, Justin G et al. (2018) Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients. Am J Public Health 108:946-950
Hu, Jiemiao; Sun, Chuang; Bernatchez, Chantale et al. (2018) T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. Clin Cancer Res 24:2920-2934
DeKroon, Robert M; Gunawardena, Harsha P; Edwards, Rachel et al. (2018) Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. MBio 9:
Bailey, Rachel M; Armao, Diane; Nagabhushan Kalburgi, Sahana et al. (2018) Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy. Mol Ther Methods Clin Dev 9:160-171
Liu, E; Tong, Y; Dotti, G et al. (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32:520-531
Slaughter, Mariesa J; Shanle, Erin K; McFadden, Andrew W et al. (2018) PBRM1 bromodomains variably influence nucleosome interactions and cellular function. J Biol Chem 293:13592-13603
Li, Bo; Tunc-Ozdemir, Meral; Urano, Daisuke et al. (2018) Tyrosine phosphorylation switching of a G protein. J Biol Chem 293:4752-4766
Dusetzina, Stacie B; Huskamp, Haiden A; Winn, Aaron N et al. (2018) Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncol 4:e173598

Showing the most recent 10 out of 1525 publications